JZY3032 TFA
Based on 1 Customer Validation
JYZ3032 (DALTAC-1) TFA is an orally active super inhibitor of androgen receptor (AR) and p300/CBP. JYZ3032 TFA redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR-driven transcription and proliferation. JYZ3032 TFA induces deep and durable tumor regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 TFA can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C54H63ClF5N13O4
- Masse moléculaire:1088.61
-
Stockage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
|
p300 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 22Rv1 | IC50 |
1.0 nM
|
Inhibition of cell growth in AR-positive human 22Rv1 prostate cancer cells.
Inhibition of cell growth in AR-positive human 22Rv1 prostate cancer cells.
|
d |
In Vitro
JYZ3032 TFA (100 nM, Serial dilutions; 4 h pulse treatment, total 120 h) exhibits durable, sustained growth inhibitory activity in VCaP and LNCaP prostate cancer cells, with a 4-hour pulse treatment yielding comparable efficacy to continuous exposure[1].
JYZ3032 TFA potently suppresses enhancer-associated histone acetylation marks in VCaP prostate cancer cells but not in AR-negative Kelly neuroblastoma cells, demonstrating lineage selectivity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:22Rv1 prostate cancer cells
-
Concentration:1.0 nM
-
Incubation Time:120 h
-
Result:Inhibited 22Rv1 cell growth with an IC50 of 1.0 nM and a maximum inhibition (Imax) of 69%.
-
Cell Line:VCaP, LNCaP, CWR-R1 prostate cancer cells
-
Concentration:Serial dilutions
-
Incubation Time:120 h
-
Result:Exhibited potent cytotoxicity across all tested AR-positive prostate cancer cells, with superior activity relative to the combined treatment with AR-LBD inhibitor JZY3221 and p300/CBP BRD inhibitor GNE-049.
Activity was comparable to or better than the p300/CBP dual degrader CBPD-409 (HY-158113).
In Vivo
YZ3032 (60 mg/kg; p.o.) also achieves significant tumor inhibition in mice model, with good tolerance[1].
JYZ3032 TFA induces complete tumor regression and 100% survival for at least 35 days in NSG mice bearing patient-derived prostate cancer xenografts of MDA-PCa-183, significantly inhibits tumor growth in the MDA-PCa-146-12 model, and exhibits good tolerance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG (male, castrated)[1]
-
Dosage:30 mg/kg (i.p.); 60 mg/kg (p.o.)
-
Administration:i.p.; p.o.
-
Result:Induced tumor regression in 75% (12 of 16) of treated tumors.
Achieved robust tumor suppression that outperformed a combination of a p300 bromodomain inhibitor and an AR-LBD inhibitor.
Increased AR-p300 proximity in treated tumors.
Reduced ERG, PSA, MYC, Ki67, H3K27ac, and H2BK20ac signals in treated tumors.
Left AR, p300, and CBP levels unchanged.
Caused no significant changes in body weight, serum liver/kidney function, or hematologic parameters.
- Research Protocol for Endocrine Diseases
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
- Intraperitoneal/Peritoneal Dissemination Xenograft
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1088.61
-
Formule C54H63ClF5N13O4
-
SMILES
CN1N=CC(C2=CC3=C(N(C4=NN([C@H](CC5)CC[C@@H]5CN(CC6)CCN6C(C=C7)=NN=C7C(N[C@H]8CC[C@@H](CC8)N(C)C9=CC=C(C(Cl)=C9)C#N)=O)C%10=C4CN(C(C)=O)CC%10)CCC3)C=C2C(F)F)=C1.OC(C(F)(F)F)=O
-
Synonyms
DALTAC-1 TFA
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JZY3032 TFA Related Classifications
HY-184124A Related Classifications
Powered by Bioz
Keywords
- JZY3032
- DALTAC-1
- JZY 3032
- JZY-3032
- DALTAC1
- DALTAC 1
- Androgen Receptor
- Histone Acetyltransferase
- patient-derived organoids
- HEK293 cells
- p300/CBP
- LNCaP
- metastatic castration-resistant prostate cancer
- AR-positive prostate cancer cells
- 22Rv1
- VCaP
- castration-resistant prostate cancer
- androgen receptor
- Inhibitor
- inhibitor
- inhibit